TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
Tumor necrosis factor alpha (TNF) is capable of inducing regression of solid tumors. However, TNF released in response to Toll-like receptor 4 (TLR4) activation by bacterial lipopolysaccharide (LPS) is the key mediator of cytokine storm and septic shock that can cause severe tissue damage limiting a...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0227940 |
id |
doaj-aff8832bcd384418b01c7670ffe0eb0c |
---|---|
record_format |
Article |
spelling |
doaj-aff8832bcd384418b01c7670ffe0eb0c2021-03-04T11:19:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01152e022794010.1371/journal.pone.0227940TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.Gary J HaderskiBojidar M KandarCraig M BrackettIlia M ToshkovChristopher P JohnsonGeraldine M PaszkiewiczVenkatesh NatarajanAnatoli S GleibermanAndrei V GudkovLyudmila G BurdelyaTumor necrosis factor alpha (TNF) is capable of inducing regression of solid tumors. However, TNF released in response to Toll-like receptor 4 (TLR4) activation by bacterial lipopolysaccharide (LPS) is the key mediator of cytokine storm and septic shock that can cause severe tissue damage limiting anticancer applications of this cytokine. In our previous studies, we demonstrated that activation of another Toll-like receptor, TLR5, could protect from tissue damage caused by a variety of stresses including radiation, chemotherapy, Fas-activating antibody and ischemia-reperfusion. In this study, we tested whether entolimod could counteract TNF-induced toxicity in mouse models. We found that entolimod pretreatment effectively protects livers and lungs from LPS- and TNF-induced toxicity and prevents mortality caused by combining either of these agents with the sensitizer, D-galactosamine. While LPS and TNF induced significant activation of apoptotic caspase 3/7, lipid tissue peroxidation and serum ALT accumulation in mice without entolimod treatment, these indicators of toxicity were reduced by entolimod pretreatment to the levels of untreated control mice. Entolimod was effective when injected 0.5-48 hours prior to, but not when injected simultaneously or after LPS or TNF. Using chimeric mice with hematopoiesis differing in its TLR5 status from the rest of tissues, we showed that this protective activity was dependent on TLR5 expression by non-hematopoietic cells. Gene expression analysis identified multiple genes upregulated by entolimod in the liver and cultured hepatocytes as possible mediators of its protective activity. Entolimod did not interfere with the antitumor activity of TNF in mouse hepatocellular and colorectal tumor models. These results support further development of TLR5 agonists to increase tissue resistance to cytotoxic cytokines, reduce the risk of septic shock and enable safe systemic application of TNF as an anticancer therapy.https://doi.org/10.1371/journal.pone.0227940 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gary J Haderski Bojidar M Kandar Craig M Brackett Ilia M Toshkov Christopher P Johnson Geraldine M Paszkiewicz Venkatesh Natarajan Anatoli S Gleiberman Andrei V Gudkov Lyudmila G Burdelya |
spellingShingle |
Gary J Haderski Bojidar M Kandar Craig M Brackett Ilia M Toshkov Christopher P Johnson Geraldine M Paszkiewicz Venkatesh Natarajan Anatoli S Gleiberman Andrei V Gudkov Lyudmila G Burdelya TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. PLoS ONE |
author_facet |
Gary J Haderski Bojidar M Kandar Craig M Brackett Ilia M Toshkov Christopher P Johnson Geraldine M Paszkiewicz Venkatesh Natarajan Anatoli S Gleiberman Andrei V Gudkov Lyudmila G Burdelya |
author_sort |
Gary J Haderski |
title |
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. |
title_short |
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. |
title_full |
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. |
title_fullStr |
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. |
title_full_unstemmed |
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. |
title_sort |
tlr5 agonist entolimod reduces the adverse toxicity of tnf while preserving its antitumor effects. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2020-01-01 |
description |
Tumor necrosis factor alpha (TNF) is capable of inducing regression of solid tumors. However, TNF released in response to Toll-like receptor 4 (TLR4) activation by bacterial lipopolysaccharide (LPS) is the key mediator of cytokine storm and septic shock that can cause severe tissue damage limiting anticancer applications of this cytokine. In our previous studies, we demonstrated that activation of another Toll-like receptor, TLR5, could protect from tissue damage caused by a variety of stresses including radiation, chemotherapy, Fas-activating antibody and ischemia-reperfusion. In this study, we tested whether entolimod could counteract TNF-induced toxicity in mouse models. We found that entolimod pretreatment effectively protects livers and lungs from LPS- and TNF-induced toxicity and prevents mortality caused by combining either of these agents with the sensitizer, D-galactosamine. While LPS and TNF induced significant activation of apoptotic caspase 3/7, lipid tissue peroxidation and serum ALT accumulation in mice without entolimod treatment, these indicators of toxicity were reduced by entolimod pretreatment to the levels of untreated control mice. Entolimod was effective when injected 0.5-48 hours prior to, but not when injected simultaneously or after LPS or TNF. Using chimeric mice with hematopoiesis differing in its TLR5 status from the rest of tissues, we showed that this protective activity was dependent on TLR5 expression by non-hematopoietic cells. Gene expression analysis identified multiple genes upregulated by entolimod in the liver and cultured hepatocytes as possible mediators of its protective activity. Entolimod did not interfere with the antitumor activity of TNF in mouse hepatocellular and colorectal tumor models. These results support further development of TLR5 agonists to increase tissue resistance to cytotoxic cytokines, reduce the risk of septic shock and enable safe systemic application of TNF as an anticancer therapy. |
url |
https://doi.org/10.1371/journal.pone.0227940 |
work_keys_str_mv |
AT garyjhaderski tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT bojidarmkandar tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT craigmbrackett tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT iliamtoshkov tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT christopherpjohnson tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT geraldinempaszkiewicz tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT venkateshnatarajan tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT anatolisgleiberman tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT andreivgudkov tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects AT lyudmilagburdelya tlr5agonistentolimodreducestheadversetoxicityoftnfwhilepreservingitsantitumoreffects |
_version_ |
1714803951855992832 |